Microbot Medical Reveals Short Term Follow Up Outcomes From Its Pivotal Pre-Clinical Study
Portfolio Pulse from Benzinga Newsdesk
Microbot Medical has revealed short term follow up outcomes from its pivotal pre-clinical study. The study used 6 LIBERTY Systems, each reaching 8 targets, with 100% usability and technical success. No adverse events or complications were observed. The company expects to receive the final report this quarter and plans to submit the Investigational Device Exemption (IDE) application to the FDA, pending the report and completion of the verification and validation process.
October 31, 2023 | 12:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Microbot Medical's successful pre-clinical study outcomes may boost investor confidence. The company's plans to submit an IDE application to the FDA could potentially open up new opportunities.
The successful outcomes from the pre-clinical study indicate that Microbot Medical's LIBERTY Systems are performing as expected, which is likely to boost investor confidence. The company's plans to submit an IDE application to the FDA, if successful, could open up new opportunities for the company to conduct clinical trials in humans, potentially leading to new product offerings and revenue streams.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100